Identification of New Biological Markers for the Progression of Mycobacterium Abscessus-induced Lung Disease in Cystic Fibrosis

Launched by OSPEDALE SAN RAFFAELE · May 9, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a type of lung disease caused by a bacteria called Mycobacterium abscessus, specifically in patients who have cystic fibrosis. The goal is to find new biological markers, which are indicators that can help us understand how this lung disease develops and worsens over time. By learning more about the body’s response to this bacteria, researchers hope to improve care for patients with cystic fibrosis and their lung health.

To participate in this study, individuals must be at least 18 years old and have a confirmed diagnosis of cystic fibrosis. Both men and women can join, but participants need to be able to understand the study's instructions and provide informed consent. If you decide to take part, you can expect to undergo tests and evaluations that will help researchers gather important information about how your lung disease progresses. This study is currently recruiting participants, and your involvement could contribute to valuable insights for the future treatment of cystic fibrosis-related lung issues.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with a certain diagnosis of cystic fibrosis and visited during normal clinical practice, in accordance with the standard operating procedures in force at the Centres.
• • Both sexes
• • Age \>18 years
• • Obtaining informed consent for patients (based on the procedures established by the protocol).
• Exclusion Criteria:
• • Patients unable to understand the instructions and information provided and be able to adequately accept the study methods.